(VIANEWS) – RAMSAY GEN SANTE (GDS.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| RAMSAY GEN SANTE (GDS.PA) | €20.60 | 18.41% | 5.08% |
| BOIRON (BOI.PA) | €39.72 | 2.73% | 8.64% |
| MEDISTIM (MEDI.OL) | kr203.00 | 2.21% | 32.37% |
| IPSEN (IPN.PA) | €103.00 | 1.08% | 12.52% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. RAMSAY GEN SANTE (GDS.PA)
18.41% Forward Dividend Yield and 5.08% Return On Equity
Ramsay Générale de Santé SA operates healthcare facilities in France, Sweden, Norway, Denmark, and Italy. It operates proximity care centers, and clinics and specialized hospitals; and provides primary medicine, medicine surgery obstetrics (MSO) dialysis, oncology, medical imaging, medical care, follow-up and rehabilitation care, home care and hospitalization, mental health care, and addiction treatment, telemedicine e health, elderly, emergency, maternity, nutrition, obesity and eating disorders, sanitary transport, outpatient surgery and eras, and SMR services. The company was formerly known as Générale de Santé SA and changed its name to Ramsay Générale de Santé SA in December 2015. Ramsay Générale de Santé SA was founded in 1987 and is headquartered in Paris, France. Ramsay Générale de Santé SA operates as a subsidiary of Ramsay Health Care Limited.
Earnings Per Share
As for profitability, RAMSAY GEN SANTE has a trailing twelve months EPS of €0.45.
PE Ratio
RAMSAY GEN SANTE has a trailing twelve months price to earnings ratio of 45.78. Meaning, the purchaser of the share is investing €45.78 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.08%.
More news about RAMSAY GEN SANTE.
2. BOIRON (BOI.PA)
2.73% Forward Dividend Yield and 8.64% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.74.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 14.5. Meaning, the purchaser of the share is investing €14.5 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.64%.
Moving Average
BOIRON’s worth is way under its 50-day moving average of €47.86 and way under its 200-day moving average of €44.60.
Yearly Top and Bottom Value
BOIRON’s stock is valued at €39.72 at 21:30 EST, way under its 52-week high of €56.50 and higher than its 52-week low of €37.00.
Volume
Today’s last reported volume for BOIRON is 2222 which is 81.74% below its average volume of 12169.
Revenue Growth
Year-on-year quarterly revenue growth declined by 6.6%, now sitting on 517.36M for the twelve trailing months.
More news about BOIRON.
3. MEDISTIM (MEDI.OL)
2.21% Forward Dividend Yield and 32.37% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.42.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 31.62. Meaning, the purchaser of the share is investing kr31.62 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MEDISTIM’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
MEDISTIM’s stock is valued at kr203.00 at 21:30 EST, way under its 52-week high of kr312.50 and way above its 52-week low of kr170.50.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.5%, now sitting on 526.89M for the twelve trailing months.
More news about MEDISTIM.
4. IPSEN (IPN.PA)
1.08% Forward Dividend Yield and 12.52% Return On Equity
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Earnings Per Share
As for profitability, IPSEN has a trailing twelve months EPS of €4.89.
PE Ratio
IPSEN has a trailing twelve months price to earnings ratio of 21.06. Meaning, the purchaser of the share is investing €21.06 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.52%.
More news about IPSEN.
